According to The Fly, valeant Pharm International (VRX) has received a rating update from a Wall Street analyst today. Analyst Louise Chen from Cantor Fitzgerald reiterated a Buy rating
Chen noted:
“We rate BHC as 12-month price target of C$32. A greater appreciation for BHC’s solid execution and future growth prospects under the new management team should drive upwards earnings revisions in 2019+, multiple expansion, and BHC shares higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of C$32.”
According to TipRanks.com, Chen is a 4-star analyst with an average return of 6.2% and a 35.8% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Amneal Pharmaceuticals Inc, and Aridis Pharmaceuticals Inc.
Read also: MYOS RENS Technology (MYOS) Stock Fires Up to the Roof; Here’s Why
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Valeant Pharm International.
Based on Valeant Pharm International’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of C$457 million. In comparison, last year the company had a net profit of C$1.63 billion.
Bausch Health Cos., Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products.
